

(This is only an advertisement for information purposes and is not a Prospectus announcement.)



ACHYUT HEALTHCARE LIMITED

Corporate Identification Number: U67120GJ1996PLC028600

Our Company was incorporated as 'Achyut Securities Private Limited' on January 11, 1996 as a private limited company under the Companies Act, 1956 with the Registrar of Companies, Gujarat, Dadra and Nagar Haveli. Pursuant to a special resolution of our Shareholders passed in the extra-ordinary general meeting held on October 28, 2002 the name of our Company was changed to 'Achyut Healthcare Private Limited', and a fresh certificate of incorporation dated November 26, 2002 was issued to our Company by the Registrar of Companies, Gujarat at Ahmedabad. Subsequently, pursuant to a special resolution of our Shareholders passed in the extra-ordinary general meeting held on November 8, 2021, our Company was converted from a private limited company to public limited company and consequently, the name of our Company was changed to 'Achyut Healthcare Limited', and a fresh certificate of incorporation dated November 30, 2021 was issued to our Company by the Registrar of Companies, Gujarat at Ahmedabad.

Registered Office: 610 Colanade, B/H Iscon Temple, Opposite Iscon, BRTS Bus Stand, Iscon - Ambali Road, Ahmedabad - 380 058, Gujarat, India
Telephone: +91 079 4898 2691 | E-mail: compliance@achyuthealthcare.com | Website: www.achyuthealthcare.com
Contact Person: Mr. Paragkumar Sandipkumar Dave, Company Secretary and Compliance Officer

OUR PROMOTERS: MR. MAHENDRA CHATRABHUJ RAYCHA AND MR. AKSHIT MAHENDRA RAYCHA

BASIS OF ALLOTMENT

PUBLIC ISSUE OF 18,00,000 EQUITY SHARES OF FACE VALUE ₹ 10 EACH ("EQUITY SHARES") OF ACHYUT HEALTHCARE LIMITED (THE "AHL" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 20.00 PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹ 10.00 PER EQUITY SHARE) (THE "ISSUE PRICE"), AGGREGATING ₹ 360.00 LACS ("ISSUE") OF THE ISSUE, 96,000 EQUITY SHARES AGGREGATING TO ₹ 19.20 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 17,04,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT AN ISSUE PRICE OF ₹ 20.00 PER EQUITY SHARE AGGREGATING TO ₹ 340.80 LAKHS IS HERINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.70% AND 25.28%, RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF THE COMPANY.

THE FACE VALUE OF EQUITY SHARES IS ₹ 10/- EACH.

THE ISSUE PRICE OF ₹ 20/- PER EQUITY SHARE WAS 2.0 TIMES OF THE FACE VALUE.

ISSUE OPENED ON: THURSDAY, MARCH 17, 2022 AND CLOSED ON: TUESDAY, MARCH 22, 2022

This issue was made in terms of chapter IX of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the "SEBI ICDR REGULATIONS"), as amended in terms of rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR"), the Issue was made for at least 25% of the post-issue paid-up equity share capital of our company. This Issue is a fixed price issue and allocation in the net issue to the public was made in terms of regulation 253 of the SEBI ICDR Regulations, as amended. For further details, please refer to section titled "Issue Procedure" beginning on Page No. 157 of the Prospectus.

Listing: The Equity Shares of our Company issued through the Prospectus are proposed to be listed on the SME Platform of BSE Limited, in terms of the Chapter IX of the SEBI ICDR Regulations as amended from time to time. Our Company has received an In-Principle approval letter dated February 16, 2022 from BSE Limited ("BSE") for using its name in the Offer document for listing of our shares on the SME Platform of BSE Limited. For the purpose of this Issue, BSE Limited shall be the Designated Stock Exchange. Our Company will file listing application on or before March 29, 2022 with BSE. The trading is proposed to be commenced on or before March 30, 2022 (Subject to receipt of listing and trading approvals from BSE).

SUBSCRIPTION DETAILS

The Issue has received 1,022 applications for 74,16,000 Equity shares (before rejections, before application not banked but after Invalid Multiple/Duplicate applications) including Market Maker Application of 96,000 Equity Shares. The Issue was subscribed to the extent of 4.1200 times as per the bid book received from BSE (before rejections, before application not banked but after Invalid Multiple/Duplicate application). After considering the technical rejections cases, the Issue was subscribed 4.0833 times.

The details of application received (Before Technical Rejection but after application not banked and application banked but application not registered)

CATEGORY	NUMBER OF APPLICATIONS	% OF TOTAL	NUMBER OF EQUITY SHARES APPLIED	SUBSCRIPTION
Market Maker	1	2.06	96,000	1.00
Other than Retail Individual Investors	62	33.68	15,66,000	1.84
Retail Individual Investors	498	64.26	29,88,000	3.51
Total	561	100.00	46,50,000	2.58

Summary of Valid Applications (after Technical and multiple rejections):

Category	Gross		Less: Rejections		Valid		Subscription (based on reservation in the Prospectus)
	Number of Applications	Equity Shares applied	Number of Applications	Equity Shares applied	Number of Applications	Equity Shares applied	
Market Maker	1	96,000	0	0	1	96,000	1.00
Other than Retail Individual Investors	62	15,66,000	0	0	62	15,66,000	1.84
Retail Individual Investors	498	29,88,000	11	66,000	487	29,22,000	3.43
Total	561	46,50,000	11	66,000	550	45,84,000	2.55

ALLOCATION: The Basis of Allotment was finalized in consultation with the Designated Stock Exchange-BSE Limited on March 25, 2022.

A. Allocation to Market Maker (After Technical Rejections): The Basis of Allotment to the Market Maker, at the Issue Price of ₹ 20/- per Equity Share, was finalized in consultation with BSE Limited. The category was subscribed by 1.00 time. The total number of Equity Shares allotted in this category is 96,000 Equity Shares in full out of reserved portion of 96,000 Equity Shares.

B. Allocation to Retail Individual Investors (After Technical Rejections): The Basis of Allotment to the Retail Individual Investors, at the Issue Price of ₹ 20/- per Equity Share, was finalized in consultation with BSE Limited. The category was subscribed by 3.43 times. Total number of Equity Shares allotted in this category is 11,10,000 Equity Shares. The category wise basis of allotment is as under:

No. of Equity Shares Applied for (Category wise)	No. Of Applications received	% to total	Total No. of Equity Shares applied	% to total	Proportionate Shares Available	Allocation per Applicant (Before Rounding Off)	Allocation per Applicant (After Rounding Off)	Ratio of Allottee's To Applicant	Total No. of Equity Shares allotted	% to total	Surplus/ Deficit
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
6,000	487	100	29,22,000	100.00	11,10,000	2,279.26	6,000	185:487	11,10,000	100.00	0

C. Allocation to Other than Retail Individual Investor (After Technical Rejection): The Basis of Allotment to other than Retail Individual Investors, at the Issue Price of ₹ 20/- per Equity Share, was finalized in consultation with BSE Limited. The category was subscribed by 1.84 times. Total number of Equity Shares allotted in this category is 5,94,000 Equity Shares. The category wise basis of allotment is as under:

No. of Equity Shares Applied for (Category wise)	No. Of Applications received	% to total	Total No. of Equity Shares applied	% to total	Proportionate Shares Available	Allocation per Applicant (Before Rounding Off)	Allocation per Applicant (After Rounding Off)	Ratio of Allottee's To Applicant	Total No. of Equity Shares allotted	% to total	Surplus/ Deficit
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
12,000	28	45.16	3,36,000	21.46	1,27,448	4,551.72	6,000	3 4	1,26,000	21.21	-1,448
18,000	15	24.19	2,70,000	17.24	1,02,414	6,827.59	6,000	1 1	90,000	15.15	-12,414
							6,000	2 15	12,000	2.02	12,000
24,000	6	9.68	1,44,000	9.20	54,621	9,103.45	6,000	1 1	36,000	6.06	-18,621
							6,000	1 2	18,000	3.03	18,000
30,000	3	4.84	90,000	5.75	34,138	11,379.31	12,000	1 1	36,000	6.06	1,862
36,000	2	3.23	72,000	4.60	27,310	13,655.17	12,000	1 1	24,000	4.04	-3,310
48,000	1	1.61	48,000	3.07	18,207	18,206.90	18,000	1 1	18,000	3.03	-207
60,000	1	1.61	60,000	3.83	22,759	22,758.62	24,000	1 1	24,000	4.04	1,241
84,000	4	6.45	3,36,000	21.46	1,27,448	31,862.07	30,000	1 1	1,20,000	20.20	-7,448
							6,000	1 4	6,000	1.01	6,000
90,000	1	1.61	90,000	5.75	34,138	34,137.93	36,000	1 1	36,000	6.06	1,862
1,20,000	1	1.61	1,20,000	7.66	45,517	45,517.24	48,000	1 1	48,000	8.08	2,483
Total	62	100	15,66,000	100	5,94,000				5,94,000	100	0

The Board of Directors of the Company at its meeting held on March 25, 2022 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange viz. BSE Limited and authorized corporate action for allotment of shares in dematerialized form to various successful applicants.

The CAN and allotment advice and/or notices shall be dispatched to the address of the Applicants as registered with the depositories / as filled in the application form on or before March 28, 2022. Further, the instructions to SCSBs has been issued on March 25, 2022 for unblocking of funds. The request for electronic credit of Equity Shares will be made to Depositories on or before March 28, 2022. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. In case the same is not received within prescribed time, Investors may contact the Registrar to the Issue at the address given below. The Company is taking steps to get the Equity Shares admitted for trading on the SME Platform of BSE Limited within six working days from the date of the closure of the Issue. Our Company will file listing application on or before March 29, 2022 with BSE. The trading is proposed to be commenced on or before March 30, 2022 (Subject to receipt of listing and trading approvals from BSE).

INVESTORS PLEASE NOTE

The details of the allotment made will be hosted on the website of the Registrar to the Issue at www.kfintech.com. All future correspondence in this regard may kindly be addressed to the Registrar quoting full name of the First/ Sole applicant, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:



KFIN TECHNOLOGIES LIMITED

(Formerly known as KFin Technologies Private Limited)
Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District,
Nanakramguda, Serilingampally, Hyderabad -500 032, Telangana
Tel: +91 040 6716 2222 | Fax: +91 040 2343 1551

Email: achyut.ipo@kfintech.com | Website: www.kfintech.com

Investor Grievance Email: einward.ris@kfintech.com

Contact Person: M Murali Krishna | SEBI Registration Number: INR000000221

On behalf of the Board of Directors
For Achyut Healthcare Limited

Sd/-
Mr. Jigen Jagdishbhai Modi
Managing Director

DIN: 03355555

Place: Ahmedabad
Date: March 25, 2022

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF ACHYUT HEALTHCARE LIMITED.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus.

ACHYUT HEALTHCARE LIMITED is proposing, subject to market conditions, public issue of its equity shares and has filed the Prospectus with the Registrar of Companies, Gujarat. The Prospectus is available on the website of SEBI at www.sebi.gov.in, the website of the Lead Manager at www.gyrcapitaladvisors.com, website of the BSE Limited at www.bseindia.com and website of Issuer Company at www.achyuthealthcare.com. Investors should note that investment in Equity Shares involves a high degree of risk. For details, investors shall refer to and rely on the Prospectus including the section titled "Risk Factors" beginning on Page No. 20 of the Prospectus, which has been filed with ROC. The Equity Shares have not been and will not be registered under the US Securities Act (the "Securities Act") or any state securities law in United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in the Regulation S under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act of 1933.